Australian Super Pty LTD Incyte Corp Transaction History

Australian Super Pty LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 21, 2023	BUY	$70.23 - $86.01 $640,638 - $784,583	9,122 Added 1.99%	467,640 $33.8 Million
Q4 2022 Feb 01, 2023	BUY	$67.18 - $84.11 $3.44 Million - $4.31 Million	51,249 Added 12.58%	458,518 $36.8 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $5.09 Million - $6.37 Million	-76,884 Reduced 15.88%	407,269 $27.1 Million
Q2 2022 Jul 13, 2022	BUY	$66.18 - $83.18 $6.03 Million - $7.58 Million	91,090 Added 23.17%	484,153 $36.8 Million
Q1 2022 Apr 29, 2022	BUY	$66.02 - $79.71 $7.48 Million - $9.03 Million	113,225 Added 40.46%	393,063 $31.2 Million
Q4 2021 Jan 24, 2022	BUY	$63.34 - $74.11 $9.55 Million - $11.2 Million	150,829 Added 116.91%	279,838 $20.1 Million
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $8.86 Million - $10.8 Million	129,009 New	129,009 $8.87 Million
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $2.61 Million - $3.46 Million	-34,392 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$80.74 - $97.7 $2.78 Million - $3.36 Million	34,392 New	34,392 $2.99 Million

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Australian Super Pty LTD, based on Form 13F filings with the SEC.

Stay updated on Australian Super Pty LTD with notifications on news.